| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'DTPA' found in 5 terms [] and 38 definitions []
| previous 26 - 30 (of 43) nextResult Pages : [1] [2 3 4 5 6 7 8 9] | | | | Searchterm 'DTPA' was also found in the following services: | | | | |
| | |
| |
|
(Gd) Gadolinium is a Lanthanide element that is paramagnetic in its trivalent state.
This paramagnetic substance is used for MR imaging because of the effect of strongly decreasing the T1 relaxation times of the tissues to which gadolinium has access. When injected during magnetic resonance imaging, gadolinium will tend to change signal intensities by shortening the T1 time in its surroundings.
The relaxivity of gadolinium is an important measure of its efficacy, which is dependent on the chemical properties of the complex. The gadolinium ion cannot be used in its chloride, sulfate, or acetate forms because of poor tolerance and low solubility in water in the neutral pH range. Although toxic by itself, gadolinium can be given safely in a chelated form such as DTPA, that still retains much of its strong effect on relaxation times ( relaxivity).
See also Dotarem®, Gadovist®, MultiHance®, Omniscan®, OptiMARK®, and Contrast Agents, the info sheet gives an overview and more in-dept information about different types of MRI contrast agents. | | | | | | | | | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | Searchterm 'DTPA' was also found in the following service: | | | | |
| | |
| |
|
Short name: (Gd-DTPA)-17, 24 cascade polymer, generic name: Gadomer-17, 24, central moiety: Gd2+, relaxivity: r1=11.9, B0=1.0 T, r2=16.5, Dose: 0.05 mmol/kg
An intravascular macromolecular MRI contrast agent with positive enhancement under development ( Bayer Schering Pharma AG) for MR angiography and tumor differentiation. The synthetic dendrimer with large molecular weight (17kD - limits agent to vascular space) is linked to Gadolinium.
The renal excretion is slowed to intermediate molecular size. In MRA a longer lasting venous and arterial enhancement was seen with Gadomer-17 due to the particular pharmacokinetics of this agent.
See also Tumor Specific Agents, and Intravascular Contrast Agents. | | | | • View the DATABASE results for 'Gadomer 17' (3).
| | | • View the NEWS results for 'Gadomer 17' (1).
| | | | Further Reading: | News & More:
|
|
| |
| | | | | |
| |
|
| | | | • View the DATABASE results for 'Gadopentetate Gastrointestinal' (3).
| | | | |
| | | Searchterm 'DTPA' was also found in the following services: | | | | |
| | |
| |
|
| | | | • View the DATABASE results for 'Gadophrin' (5).
| | | | |
| | | Searchterm 'DTPA' was also found in the following service: | | | | |
| | |
| |
|
Short name: Gd-DTPA-BMEA, generic name: Gadoversetamide
A paramagnetic extracellular MRI contrast agent with positive enhancement. When placed in a magnetic field, gadoversetamide decreases T1 and T2 relaxation times in tissues where it accumulates. At the recommended dose, the effect is primarily on T1
relaxation time, and produces an increase in signal intensity (brightness). See Contrast Agents and OptiMARK™. | | | | • View the DATABASE results for 'Gadoversetamide' (3).
| | | • View the NEWS results for 'Gadoversetamide' (1).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | |
| | | |
|
| |
| Look Ups |
| |